Weimiao YU


Dr. Yu Weimiao is an image processing and AI/ML expert in bioimage informatics and computational digital pathology diagnosis. He is currently a joint PI of IMCB and BII, where he leads two groups to address challenging problems in the field. Dr. Yu obtained his Ph.D. from the National University of Singapore (NUS) in 2007, majoring in image processing and machine vision. He joined the Agency of Science, Technology, and Research(A*STAR) in 2007 and joined the Institute of Molecular and Cell Biology (IMCB) in 2010. He is currently heading the Computational & Molecular Pathology Lab (CMPL) in IMCB; where he strives to deepen and extend the R&D with clinical and industrial partners. His research interests are Computational Biomedical Image Analysis and Quantitative Imaging Informatics based on AI and machine learning. His research outcomes were published in top international peer-reviewed journals, such as Nature Cell Biology, Nature Communication and Current Biology. 

Dr. Yu and his teams focus on driving the quantitative and reliable cellular/ molecular image analysis and diagnosis solutions from academic research to clinical decision making, i.e., diagnosis and prognosis. His team has more than 14 years of experience designing and fast prototyping robust cellular image analysis and molecule diagnosis solutions. The previous research and development projects with hospitals, biotech, and pharmaceutical companies have equipped his teams with solid skills and expertise in medical algorithm development and validation. His teams integrate methodologies from multiple fields, such as, signal processing, image processing and computer vision, optimization, machine learning, pattern recognition, mathematical modelling, Artificial Intelligence (AI), and Deep Learning (DL) with the input of pathologists, oncologists, and cell biologists. The goal is to provide efficient, economic, accurate, and robust digital pathology algorithms for patients and clinicians, and improve public healthcare.

On top of an active academic career, Dr. Yu is also an entrepreneur. To enhance the application of machine learning and AI in clinical diagnosis/prognosis, he co-founded a biotech company, known as A!maginostic Pte. Ltd. Dr. Yu has established close collaborations with the Pathology department of two clinical research centres, Singapore General Hospital (SGH) and the National University Hospital (NUH), to ensure a smooth R&D pipeline of developing computational digital pathology solutions. Dr. Yu has established a world-class joint lab of excellence for immunodiagnostics at the tissue level. His team provides intelligent and quantitative imaging analysis solutions for clinical pathology images for diagnostic and prognostic purposes. It includes the following three solutions: i). ImmunoHistoChemistry (IHC) and Immunofluorescence (IF); ii). Hematoxylin&Eosin (H&E) and iii). Multiplex Fluorescence (MF) stained images. The automatic processing of integrated imaging modalities will provide more comprehensive information for clinicians to make better decisions for patients. Such a platform allows the researchers, clinicians, and pharma companies to profile the patient immune signature for diagnosis, prognosis and drug response study.

The joint lab of excellence is based at the A*STAR Research Support Centre: 
https://www.rsc.a-star.edu.sg/technologyplatforms/scientific-side-menu/scientific-information/histopathology/model-based-digital-pathology-services

 


Our Team
Research
Publications